Cancer Drug Resistance is a premier journal published by OAE PUBLISHING INC, focusing on the critical field of oncology and pharmacology. Since its inception in 2018, the journal has been at the forefront of presenting innovative research aimed at understanding and overcoming drug resistance in cancer therapy. With an impressive impact factor reflected in its Q2 ranking in Cancer Research and a Q1 ranking in Pharmacology (medical) for 2023, Cancer Drug Resistance serves as a vital resource for researchers, clinicians, and students who are dedicated to advancing cancer treatment and improving patient outcomes. The journal's commitment to disseminating high-quality, peer-reviewed articles underscores its importance within the academic and medical communities. While it operates on an open-access model, facilitating widespread distribution and access to crucial research findings, the journal continuously strives to foster dialogue and collaboration among stakeholders in cancer research and pharmacology. Its mission is clear: to shine a light on the evolving challenges and breakthroughs in drug resistance, paving the way for enhanced therapeutic strategies and clinical solutions.

Molecular Therapy Oncolytics is an esteemed Open Access journal published by CELL PRESS, focusing on cutting-edge research in the fields of oncology, molecular medicine, and pharmacology. Established in 2014, the journal has quickly gained a prominent position in the academic community, reflected in its impressive Q1 and Q2 rankings across various categories including Cancer Research, Molecular Medicine, and Pharmacology. With an impactful presence in the UK and a strong international readership, it aims to disseminate significant advancements in therapeutic strategies targeted at cancer treatment and management. By providing a platform for peer-reviewed research, Molecular Therapy Oncolytics plays a critical role in bridging the gap between scientific innovation and clinical application, making it an invaluable resource for researchers, healthcare professionals, and students striving to contribute to the evolving landscape of oncology.

Cancer Research Communications is an esteemed journal published by the American Association for Cancer Research, a leading organization in the field of oncology. This journal aims to advance knowledge in cancer research through the dissemination of high-quality, peer-reviewed articles that cover a wide range of topics related to cancer biology, treatment modalities, and prevention strategies. As an open-access journal, Cancer Research Communications ensures that vital research findings are accessible to a global audience, promoting collaboration and innovation within the scientific community. The journal serves as a crucial platform for researchers, professionals, and students to share their insights and foster the exchange of effective cancer therapies and methodologies. With a commitment to excellence, it plays a significant role in shaping the future of cancer research and therapeutic development.

Cancer Cell International, published by BMC, is a transformative open-access journal established in 2001, dedicated to advancing the field of oncology and cancer research. With its ISSN number not specified and an E-ISSN of 1475-2867, the journal proudly operates from the United Kingdom, located at CAMPUS, 4 Crinan St, London N1 9XW, England. Renowned for its rigorous peer-review process, Cancer Cell International has made significant strides, securing a Q2 ranking in Cancer Research and Q1 rankings in both Genetics and Oncology as of 2023. It ranks impressively in Scopus, featuring in the top quintile of Genetics (#37/347) and Oncology (#52/404), indicating its importance within the scientific community. The journal's broad scope caters to a diverse array of topics within cancer biology, making it an invaluable resource for researchers, professionals, and students seeking to stay at the forefront of cancer science. With a commitment to disseminating high-quality research, Cancer Cell International invites scholars to explore innovative findings and contribute to the collective effort of combating cancer.

ONCOLOGY RESEARCH, published by TECH SCIENCE PRESS, is a vital academic journal dedicated to the rapidly evolving field of oncology. With its ISSN 0965-0407 and E-ISSN 1555-3906, the journal serves as a key resource for researchers, clinicians, and academicians committed to advancing cancer research and treatment strategies. Operating without an Open Access model, ONCOLOGY RESEARCH provides high-quality, peer-reviewed articles that cover diverse topics within cancer research, medicine, and oncology, with its 2023 Scopus ranking placing it in the Q3 quartile. The journal's commitment to facilitating rigorous scientific discourse is evident in its historical breadth, with a publishing history dating back to 1992. ONCOLOGY RESEARCH is not only significant for the academic community but also plays a critical role in fostering new insights and approaches in the fight against cancer, making it a must-read for those involved in this critical area of study.

Cancer Treatment Reviews, published by Elsevier Science Ltd, is a leading international journal dedicated to the exploration and advancement of therapeutic strategies in oncology. With an impressive impact factor that reflects its status in the field, this journal is classified within Q1 quartile rankings in Medicine (Miscellaneous), Oncology, and Radiology, Nuclear Medicine and Imaging, as of 2023. The journal has a rich lineage, having been established in 1974 and consistently evolving to encompass the latest breakthroughs and methodologies in cancer treatment. A vital resource for researchers, clinicians, and students alike, it aims to promote understanding and application of effective interventions, thereby contributing to improvements in patient outcomes. By prioritizing high-quality reviews, Cancer Treatment Reviews plays an essential role in bridging the gap between current research and clinical practice, making it an indispensable asset in the continuous fight against cancer.

Blood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.

CELLULAR ONCOLOGY is an esteemed open access journal published by SPRINGER since 2004, specializing in the dynamic field of oncological research. With its ISSN 2211-3428 and E-ISSN 2211-3436, this journal plays a pivotal role in disseminating cutting-edge findings and innovative methodologies that address cancer at the cellular level. The journal has consistently achieved high-impact recognition, currently holding a Q2 rating in Cancer Research and Q1 rankings in Medicine (miscellaneous), Molecular Medicine, and Oncology as of 2023. Furthermore, it ranks 56th in oncology medicine and 48th in cancer research according to Scopus, placing it firmly within the top echelons of its field. Published in the Netherlands, with an aim to connect scientists, clinicians, and practitioners worldwide, CELLULAR ONCOLOGY fosters a collaborative environment for researchers to share insights, enhance understanding, and advance treatments. The journal’s open access model ensures that ground-breaking research is freely available, facilitating greater visibility and impact within the scientific community and beyond.

Cancer and Metastasis Reviews, published by Springer, is a leading journal in the field of oncology and cancer research. With an impressive impact factor placing it in the Q1 category for both Cancer Research and Oncology as of 2023, this journal is ranked 29th out of 404 in Medicine, Oncology, and 22nd out of 230 in Biochemistry, Genetics, and Molecular Biology, reflecting its significant influence and prestige in the academic community. Established in 1982, the journal covers a wide spectrum of topics related to the mechanisms of cancer progression and metastasis, making it an essential resource for researchers, healthcare professionals, and students dedicated to understanding and tackling cancer. Although the journal does not provide open access options, the impactful research it publishes contributes to advances in therapeutic strategies and enhances the collective knowledge surrounding cancer pathophysiology. With research converging from 1982 to 2024, Cancer and Metastasis Reviews continues to be a vital platform for disseminating high-quality scientific information in the ever-evolving landscape of cancer research.

Nature Cancer, published by NATURE PORTFOLIO, stands at the forefront of oncological research with a robust impact within the scientific community. As an esteemed journal with impressive rankings—#12 in Medicine (Oncology) and #8 in Biochemistry, Genetics and Molecular Biology (Cancer Research) according to Scopus, placing it within the 97th and 96th percentiles respectively—Nature Cancer boasts a Q1 category status in both Cancer Research and Oncology for 2023. The journal's commitment to advancing cancer research is crucial, promoting high-quality, peer-reviewed studies that address the complexities of cancer biology and treatment. By facilitating open access to impactful findings, Nature Cancer aims to foster collaboration and inspire innovative approaches among researchers, professionals, and students alike, making significant strides in the global fight against cancer. As this pivotal publication continues its converged years from 2020 to 2024, it heralds a future ripe with transformative insights and breakthroughs in the vital field of oncology.